... Gynäkologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC). [email protected] 18 02 2025 19 02 2025 08 03 2025...

... the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer. [email protected] 24 03 2024 25 03 2024 10 04 2024 © 2024 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer...

... for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug...

..., AGO) presents the 2023 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC). However, the first approved selective estrogen receptor degrader elacestrant showed a clinically significant increased PFS...

... favorable therapeutic index. There is still a lack of evidence for MCT in metastatic breast cancer (MBC). In this retrospective unicenter study, we demonstrated real-word data on MCT in MBC. Methods: MBC patients who received metronomic oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5...

... treatment over the observation period or until last follow-up. Overall, 92 patients (20.5%) died during the observation period, and 92 patients (20.5%) were lost to follow-up. CDK4/6 inhibitors Metastatic breast cancer Progression-free survival Real-world data Patients diagnosed with HR...

... of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer. Circulating tumor cells represent interesting new candidates for early response evaluation (LoE 1b/A/AGO−) in the future but should not be used outside of a clinical trial [ 6...

...-dependent kinases 4/6 (CDK4/6Is) have become standard of care in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC). CV side effects are uncommon with CDK4/6Is and only include QT prolongation, with a low incidence rate. Case...

...Alexios Matikas; Athanasios Kotsakis; Maria Perraki; Dora Hatzidaki; Konstantinos Kalbakis; Emmanouil Kontopodis; Michail Nikolaou; Vasilios Georgoulias Introduction: The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well...

...Barliz Waissengrin; Roni Levin; Ido Wolf; Eliya Shachar; Amir Sonnenblick Background: Most patients with HER2-positive metastatic breast cancer (MBC) receive first-line treatment with anti-HER2 agents and have already received anti-HER2 therapy as adjuvant or neoadjuvant therapy in the local...

...Shouko Hayama; Rikiya Nakamura; Toshiko Miyaki; Makiko Itami; Naohito Yamamoto Background/Aims: The study aim was to evaluate if mTOR inhibitors can be considered as a treatment option for HR+ HER2− metastatic breast cancer (MBC) after progression on CDK4/6 inhibitors in clinical practice. Methods...

...Sabine Grill; Evelyn Klein Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able...

...Meng Lv; Yan Mao; Teng Ma; Yongmei Wang; Xiaoyi Liu; Yuhua Song; Haibo Wang Background: Fulvestrant 500 mg monotherapy is recommended as the first-line endocrine treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (MBC). It is also used in MBC maintenance...

...Thomas Kolben; Maximilian Bardenhewer; Theresa M. Kolben; Laura Rickerl; Tom Degenhardt; Sven Mahner; Nadia Harbeck; Rachel Wuerstlein Purpose: Differential efficacy of newly registered therapies in subgroups of metastatic breast cancer (MBC) is an important consideration for subsequent use...

...Constanze Elfgen; Giacomo Montagna; Seraina Margaretha Schmid; Walter Bierbauer; Uwe Güth Background: We challenge the concept of metastatic breast cancer (MBC) as a chronic disease. Methods: We analyzed an unselected cohort of 367 patients who were diagnosed with MBC over a 22-year period (1990...

...Luis Manso; Alfonso Sanchez-Muñoz; Isabel Calvo; Yann Izarzugaza; Jessica Plata; Cesar Rodriguez Summary The optimal sequence of anti-human epidermal growth factor receptor 2 (HER2) therapies in metastatic breast cancer (MBC) is still undetermined. Physicians must therefore make decisions based...

..., AGO) has been preparing and updating evidence-based recommendations for the diagnosis and treatment of patients with early and metastatic breast cancer. The AGO Breast Committee consists of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology...

... criteria. A 47-year-old female patient diagnosed with stage IV thymic carcinoma and previously treated with chemoradiation was diagnosed with metastatic breast cancer during a periodic review. Color Doppler ultrasonography showed a low-echo real occupancy in the breast. Pathological examination...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2017 Metastatic breast cancer Systemic therapy Local therapy Treatment recommendations...

...Thomas Kolben; Theresa M. Kolben; Isabelle Himsl; Tom Degenhardt; Jutta Engel; Rachel Wuerstlein; Sven Mahner; Nadia Harbeck; Steffen Kahlert Summary Background: This study aimed to identify the association of local surgery of the primary tumor in metastatic breast cancer (MBC) patients...